Clinical Trial Update: Combining Erlotinib Plus Bevacizumab and Gemcitabine Plus Capecitabine to Treat Advanced Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial investigated a four-drug combination of erlotinib, bevacizumab, gemcitabine, and capecitabine for advanced pancreatic cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Avastin (bevacizumab)
• Gemzar (gemcitabine)
• Tarceva (erlotinib)
• Xeloda (capecitabine)

Snippet

Sponsor: Royal Marsden NHS Foundation Trust | Conditions: Pancreatic Cancer | Phase 1, Phase 2 | Status: COMPLETED